Fundraising FoxTullis Health Investors — 2021 Investments
2 investments dated 2021 · listed companies and verified rows first · show all
RevBio Sciences develops Gemini, an intravenously administered formulation of phosphorylated hexaacyl disaccharide (PHAD) designed to reduce inflammation-related damage by reprogramming the innate immune system to respond to stress such as trauma and infection in an attenuated way.
BiotechHealthtechSan Diego, US
James M. Rolke(Executive Officer, Director)inJess Roper(Director)inChester S. Zygmont, III(Executive Officer)in
BoardGeorge F. Tidmarsh(Director)Jennifer Carver(Director)
Board seatCurt LaBelle· per SEC Form D · $4.4M raise · filed Apr 2021
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.